{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-025432","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.913037+00:00","generated_at":"2026-05-15T15:46:24.582058+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Protara Therapeutics Q4 net loss $17.3M; TARA-002 shows 68% CR in BCG-Unresponsive NMIBC","bullets":["Net loss Q4 2025: $17.3M ($0.37/share); FY2025: $57.4M ($1.34/share).","Cash $197.9M as of Dec 31, 2025; expects funding into 2028 after $86.3M December offering.","TARA-002 in BCG-Unresponsive NMIBC: 68.2% complete response at six months; no grade 3+ TRAEs.","FDA granted TARA-002 Breakthrough Therapy and Fast Track designations for lymphatic malformations.","Expects to complete BCG-Unresponsive cohort enrollment in 2H 2026; initiate ADVANCED-3 trial in 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-025432","json":"https://secwatch.observer/filing/0001213900-26-025432.json","markdown":"https://secwatch.observer/filing/0001213900-26-025432.md","text":"https://secwatch.observer/filing/0001213900-26-025432.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/0001213900-26-025432-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea0280404-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T15:46:24.582058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"594fbd6184af3425929e92ff2d468d4c124ffec1","claim":"Protara Therapeutics, Inc. reported financial results for the fourth quarter of 2025.","evidence_excerpt":"Research and development expenses for the fourth quarter of 2025 increased to $13.1 million from $9.5 million for the prior year period","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/0001213900-26-025432-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7b023951e82e71ce1ca735aa77ad1842a0d954a4","claim":"Protara Therapeutics, Inc. reported financial results for the full year ended December 31, 2025.","evidence_excerpt":"and for the full year increased to $42.6 million compared to $31.7 million for 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/0001213900-26-025432-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}